↓ Skip to main content

Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors

Overview of attention for article published in Clinical Cancer Research, January 2022
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news
9 news outlets
blogs
2 blogs
twitter
118 tweeters
facebook
2 Facebook pages

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
42 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors
Published in
Clinical Cancer Research, January 2022
DOI 10.1158/1078-0432.ccr-21-2275
Pubmed ID
Authors

Adam C. Palmer, Benjamin Izar, Haeun Hwangbo, Peter K. Sorger

Twitter Demographics

The data shown below were collected from the profiles of 118 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 42 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 16 38%
Other 8 19%
Student > Doctoral Student 3 7%
Student > Bachelor 3 7%
Professor 1 2%
Other 3 7%
Unknown 8 19%
Readers by discipline Count As %
Medicine and Dentistry 9 21%
Biochemistry, Genetics and Molecular Biology 5 12%
Pharmacology, Toxicology and Pharmaceutical Science 3 7%
Engineering 3 7%
Immunology and Microbiology 3 7%
Other 9 21%
Unknown 10 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 138. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 May 2022.
All research outputs
#218,545
of 21,235,767 outputs
Outputs from Clinical Cancer Research
#87
of 12,064 outputs
Outputs of similar age
#6,390
of 374,828 outputs
Outputs of similar age from Clinical Cancer Research
#7
of 117 outputs
Altmetric has tracked 21,235,767 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,064 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 374,828 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 117 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.